Cevec Pharmaceuticals GmbH, of Cologne, Germany, said it granted a license for its CAP Go technology to Biotest AG, of Dreieich, Germany, for the development, production and commercialization of candidate molecules to treat the symptoms of hemophilia patients. Under the terms, Cevec will receive service fees for ongoing development support, up-front and milestone payments as well as royalties on future product sales.